GoldenGolden
Advanced Search
Stratos Genomics

Stratos Genomics

Stratos Genomics is a DNA sequencing company founded in 2007 by Allan Stephan.

Stratos Genomics a Seattle-based DNA sequencing company focusing on Sequencing By Expansion (SBX) technology, a fourth generation DNA sequencing method that uses a biochemical reaction to encode the sequence of a DNA molecule into a measurable surrogate polymer called an Xpandomer. Applications of SBX include targeted oncology panels and whole-genome sequencing to rapidly diagnosing infectious diseases.

Timeline

January 8, 2018
Stratos Genomics raises a $20,000,000 series B round from Fisk Ventures.
June 16, 2015
Stratos Genomics raises a $15,000,000 series B round from Fisk Ventures and Roche Venture Fund.
May 13, 2014
Stratos Genomics raises a $10,000,000 series B round from Fisk Ventures and Roche Venture Fund.
September 4, 2013
Stratos Genomics raises a $2,000,000 venture round.
October 10, 2012
Stratos Genomics raises a $2,000,000 venture round.
August 25, 2011
Stratos Genomics raises a $829,000 grant.
June 8, 2011
Stratos Genomics raises a $2,100,000 series A round from Fisk Ventures.
September 7, 2010
Stratos Genomics raises a $4,000,000 series A round.

Funding rounds

People

Name
Role
LinkedIn

Nagaraj Ananthapadmanabhan

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Mark Terry
May 22, 2020
BioSpace
Roche hopes to advance the development of its own nanopore sequencer, which would use a new approach combining electronic and biological components to sequence DNA quickly and at low cost.
Reuters Editorial
May 22, 2020
U.S.
Pharmaceutical group Roche has acquired U.S.-based Stratos Genomics to further develop DNA-based sequencing for diagnostic use, it said on Friday.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.